Special Extramural COVID-19 Funding Opportunities

NIH Opportunities

For Coronavirus Disease 2019 (COVID-19): Information for NIH Applicants and Recipients of NIH Funding and the current Funding Opportunities Specific to COVID-19, please visit https://grants.nih.gov/policy/natural-disasters/corona-virus.htm.

Emergency Awards: Notice of Special Interest (NOSI) on Pan-Coronavirus Vaccine Development Program Projects
(NOT-AI-21-002) National Institute of Allergy and Infectious Diseases

NIAID is issuing this Notice of Special Interest (NOSI) to highlight the critical need to develop prophylactic vaccines able to provide broad and durable protection against coronaviruses (CoVs), especially SARS-CoV-2 and others with pandemic potential. NIAID is particularly interested in highly collaborative, multi-disciplinary Program Projects (P01s) that incorporate understanding of CoV virology and immunology, immunogen design, and innovative vaccine and adjuvant platforms and technologies to discover, design, and develop pan-coronavirus (pan-CoV) vaccine candidates that provide broad protective immunity to multiple CoV strains. Applications in response to this NOSI must be submitted using the following funding opportunity: PAR-20-072; NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed). Applications will be received on two receipt date: June 11, 2021.

Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection
(NOT-DA-20-084) National Institute on Drug Abuse

The purpose of this notice is to communicate NIDA’s interest in supporting research on the effects of smoking or vaping tobacco or marijuana on the risk of acquiring COVID-19 and the clinical course of the infection. First available due date is January 4, 2021 and subsequent receipt dates through September 8, 2024. 

Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice.

  • PA-20-183 - NIH Research Project Grant (Parent R01 Clinical Trial Required)
  • PA-20-200 - NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
  • PA-20-195- NIH Exploratory/Developmental Research Grant (Parent R21Clinical Trial Not Allowed)

Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)
(NOT-TR-21-006) National Center for Advancing Translational Sciences

National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel coronavirus (SARS-CoV-2) and the disease it causes, i.e., “coronavirus disease 2019” (COVID-19). NCATS is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair.  This notice applies to receipt dates on or after October 30, 2020 and subsequent receipt dates through March 16, 2021. Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice.

  • PAR-17-465 Bench Testing Therapeutic/Indication Pairing Strategies (UG3/UH3)
  • PAR-18-462 Clinical Trial Planning: Therapeutic/Indication Pairing Strategies (U34 Clinical Trial Not Allowed)
  • PAR-18-332 Clinic Testing Therapeutic/Indication Pairing Strategies (U01 Clinical Trial Required)

Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI)
(NOT-HL-20-814) National Heart, Lung, and Blood Institute

The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants of the special interest of NHLBI in research to understand host resilience as a critical determinant of outcomes in acute respiratory distress syndrome (ARDS) /acute lung injury (ALI). Application Receipt Date(s): First available due date: October 5, 2020 and subsequent receipt dates through July 6, 2024.

Notice of Special Interest: Emerging Viral Infections and their Impact on the Male and Female Reproductive Tract
(NOT-HD-20-021)

The purpose of this Notice is to invite applications proposing cutting-edge research on emerging viral infections that are thought to primarily impact non-reproductive sites, at least at initial presentation, but may also affect the male and/or female reproductive tract. The recent global outbreak of the novel coronavirus, SARS-CoV-2, is not an anomaly and will most likely not be the last virus occurrence. Application receipt date: this notice applies to due dates on or after October 5, 2020 and subsequent receipt dates through July 16, 2023. 

Notice of Special Interest: Secondary Analyses of Existing Alcohol Research Data
(NOT-AA-20-018) National Institute on Alcohol Abuse and Alcoholism

The purpose of this Notice of Special Interest (NOSI) is to solicit applications to support the secondary analyses of existing data sets with the goal of enhancing our understanding of the following: 1) the patterns and trajectories of alcohol consumption, 2) the epidemiology and etiology, including genetics, of alcohol-related problems and disorders, and 3) alcohol-related health services and health systems, including access, quality, and efficiency. This Notice encourages applications proposing innovative analyses of existing alcohol research data, answering novel research hypotheses and questions, and developing and testing advanced analytical methodologies applicable to alcohol related epidemiological, behavioral and genetics research.

First Available Due Date: October 05, 2020 and subsequent receipt dates through September 5, 2023. 

Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV-2
(NOT-AI-20-065) National Institute of Allergy and Infectious Diseases

This Notice of Special Interest encourages cooperative agreement applications for implementation of investigator-initiated high-risk clinical trials, as defined by NIAID in PAR-18-633 and NOT-AI-16-084, that will augment ongoing and planned clinical trials of therapeutic and vaccine candidates directed against SARS-CoV-2 to evaluate:

  • SARS-CoV-2 candidate vaccines
  • non-vaccine biomedical prevention of SARS-CoV-2 infection and/or COVID-19
  • therapeutic approaches to treat COVID-19

Investigators interested in responding to this NOSI are strongly encouraged to submit a written request for prior consultation to the email address listed below prior to submission of an NIAID Clinical Trial Implementation (U01) Cooperative Agreement application in response to PAR-18-633 to discuss the proposed project in the context of the needs identified above.

Applications will be accepted once a month on the following dates: April 14, 2021, May 14, 2021, June 14, 2021, July 14, 2021, August 14, 2021, September 14, 2021.   

Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed)
(PAR-20-256) National Institute of Allergy and Infectious Diseases

The purpose of this public health emergency funding opportunity is to provide Personal Protective Equipment (PPE) to directly support the needs of the NIAID’s vaccine and treatment clinical trials and clinical studies for COVID-19. This program will ensure that adequate protective equipment is available to directly assist in safely carrying out the clinical activities and direct interactions with the patients participating in the trial. Eligibility is limited to recipients conducting COVID-related clinical research and clinical studies supported by NIAID’s emergency appropriation provided by “The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020” and “The Coronavirus Aid, Relief and Economic Security (CARES) Act”.
Application Receipt Date(s): Applications for this limited competition FOA will be accepted on a rolling basis, beginning July 13, 2020. This funding mechanism expires July 08, 2021.

Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Select Research Activities related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
(NOT-AI-20-059) National Institute of Allergy and Infectious Diseases

NIAID is issuing this Notice of Special Interest (NOSI) to highlight very specific and limited needs for Competitive Revision applications to active NIAID grants in order to further build the infrastructure that NIAID needs to support the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) research response. This NOSI replaces NOT-AI-20-034 which was rescinded with this issuance of this Notice.

Applications will be accepted on a rolling basis 07/02/2020 to 07/02/2021

Notice of NIMH Participation in PA-20-135, "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"
(NOT-MH-20-064) National Institute of Mental Health

The purpose of this Notice is to inform potential applicants that the National Institute of Mental Health (NIMH) will participate, effective immediately, in PA-20-135, "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)".

NOT-AI-20-051, Notice of Special Interest (NOSI): Select Research Areas for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

National Institute of Allergy and Infectious Diseases

NIAID is issuing this Notice of Special Interest (NOSI) to highlight the need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) in select scientific areas using the following funding mechanisms.

This notice applies to due dates on or after June 16, 2020 and subsequent receipt dates through September 8, 2021.  Please see FOA for specific due dates for submission of proposals.

Related Announcements to Apply Under:

  • PA-20-200 NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
  • PA-19-272 PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
  • PA-19-270 PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)

Notice of Special Interest (NOSI): Availability of Urgent Award for Competitive Revisions to IDeA-CTR Awards to Address the Need for Documenting 2019 Novel Coronavirus Disease (COVID-19)-Related Patient Outcomes
(NOT-GM-20-033)  National Institute of General Medical Sciences

PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)

NIGMS will accept applications for Competitive Revisions to active IDeA-CTR U54 awards to rapidly provide supplementary funds to create a registry of COVID-19 patients across IDeA states that includes a comprehensive set of deidentified clinical data elements.

First available due date for this opportunity is June 18, 2020.

Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements for Coronavirus Disease 2019 (COVID-19) Research within the Mission of NIDCR

(NOT-DE-20-022)

National Institute of Dental and Craniofacial Research and Office of Research on Women's Health

The following FOA’s apply to this funding opportunity:

PA-18-591, “Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)” and

PA-18-935, “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)”

The National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19). NIDCR will place a high priority on topics that would be of immediate and high impact to protect and ensure the safety of personnel and patients in dental practices. These topics include prevention of SARS-COV-2 transmission and improvements in the detection and diagnosis of COVID-19; as well as acquisition of a more robust understanding of SARS-CoV-2 pathogenesis. Application due dates: November 2, 2020, by 5:00 PM.

Notice of Special Interest (NOSI):? Availability of Urgent Competitive Revisions and Administrative Supplements for Coronavirus Disease 2019 (COVID-19) Research within the Mission of NIDCR
(NOT-DE-20-022)
National Institute of Dental and Craniofacial Research
Office of Research on Women's Health

NIH POCTRN Rapid Acceleration of Diagnostics call for proposals

https://www.poctrn.org/radx.

Fast-Track Program for COVID-19 Test Development and Distribution

Innovative Technologies to Increase U.S. Capacity for COVID-19 Testing

NIH POCTRN is now accepting proposals for support on a rolling basis until further notice.

Through this opportunity, the NIBIB is providing substantial support to accelerate the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improvements to clinical laboratory tests, that can directly detect SARS-CoV-2, the virus that causes COVID-19. NIBIB will support the full range of product development including commercialization and product distribution. 

Notice of Special Interest: Availability of Administrative Supplements and Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIAAA

NOT-AA-20-011

Participating Organizations: (NIAAA)

Release Date: April 16, 2020

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19)

NOT-LM-20-010

Participating Organizations: (NLM)

Release Date: April 16, 2020

Notice of National Institute of Dental and Craniofacial Research (NIDCR) Participation in PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)

NOT-DE-20-020

Participating Organizations: (NIDCR), (NHGRI), (NIA), (NIAAA), (NIAID), (NIBIB), (NICHD), (NIDCR), (NIDDK), (NIDA), (NIEHS), (NIMH), (NIMHD), (NCI)

Release Date: April 14, 2020

Notice of Common Funds Participation in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"

NOT-RM-20-016

Participating Organizations: (Common Fund), (NHGRI), (NIAID), (NIBIB), (NICHD), (NIDDK), (NIEHS), (NIGMS), (NIMHD), (NCCIH), (NCI)

Release Date: April 14, 2020

Notice of Special Interest regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for the Establishment and Maintenance of a Research Database for Neurological Manifestations of the SARS-CoV-2 NOT-NS-20-046

Participating Organizations: (NINDS)

Release Date: April 14, 2020

Notice of Participation of NIAAA in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional"

NOT-AA-20-007

Participating Organizations: (NIAAA)

Release Date: April 13, 2020

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences

NOT-OD-20-097

Participating Organizations: (OBSSR), (NHLBI), (NIA), (NIAAA), (NIDDK), (NIEHS), (NCCIH), (NCI), (NICHD), (ODP), (ORWH)

Release Date: April 13, 2020

Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)

NOT-ES-20-020

Participating Organizations: (NIEHS)

Release Date: April 10, 2020

Notice of Early Expiration of NOT-ES-20-015, "Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)

NOT-ES-20-019

Participating Organizations: (NIEHS)

Release Date: April 10, 2020

NIEHS Worker Training Program Coronavirus and Infectious Disease Response Training (Admin Supp Clinical Trial Not Allowed)

NOT-ES-20-017

Participating Organizations: (NIEHS)

Release Date: April 10, 2020

Notice of Early Expiration of "Notice of Special Interest (NOSI) regarding the NIEHS Worker Training Program Coronavirus and Infectious Disease Response Training (Admin Supp Clinical Trial Not Allowed)"

NOT-ES-20-016

Participating Organizations: (NIEHS)

Release Date: April 10, 2020

Notice of Special Interest (NOSI): Availability of Emergency Competitive Revision and Administrative Supplements on Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)

NOT-EB-20-008

Participating Organizations: (NIBIB)

Release Date: April 10, 2020

Notice of Special Interest (NOSI): Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)

NOT-EB-20-007

Participating Organizations: (NIBIB)

Release Date: April 10, 2020

Notice of Special Interest (NOSI): Small Business Research and Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)

NOT-EB-20-006

Participating Organizations: (NIBIB)

Release Date: April 10, 2020

Notice of Special Interest (NOSI): Urgent Competitive Revisions to Accelerate Research on the Development of Predictive Models of the Spread of SARS-CoV-2 and Outcomes of Potential Public Health Interventions on COVID-19

NOT-GM-20-027

Participating Organizations: (NIGMS)

Release Date: April 10, 2020

Notice of Special Interest (NOSI): Availability of Administrative Supplements and Urgent Competitive Revisions for Research on Stress Management in Relation to Coronavirus Disease 2019 (COVID-19)

NOT-AT-20-011

Participating Organizations: (NCI), (NCCIH), (NIA), (NIAAA)

Release Date: April 10, 2020

Notice of Special Interest (NOSI): National Cancer Institute Announcement Regarding Availability of Urgent Competitive Revision and Administrative Supplements on Coronavirus Disease 2019 (COVID-19)

NOT-CA-20-042

Participating Organizations: (NCCIH), (NIA), (NIAAA), (NCI)

Release Date: April 10, 2020

Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) Related to HIV Comorbidities, Coinfections, and Complications within NIDDK's Mission

NOT-DK-20-020

Participating Organizations: (NIDDK)

Release Date: April 9, 2020

Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities

NOT-MD-20-019

Participating Organizations: (NIMHD)

Release Date: April 9, 2020

Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus

NOT-TR-20-017

Participating Organizations: (NCATS)

Release Date: April 9, 2020

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus

NOT-MH-20-047

Participating Organizations: (NIMH), (NIA), (NIAAA), (NIMHD), (ODP)

Release Date: April 9, 2020

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus

NOT-TR-20-016

Participating Organizations: (NCATS)

Release Date: April 9, 2020

Notice of Special Interest (NOSI): National Cancer Institute Announcement regarding Availability of Competitive Revision SBIR/STTR Supplements on Coronavirus Disease 2019 (COVID-19)

NOT-CA-20-043

Participating Organizations: (NCI)

Release Date: April 9, 2020

Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)

NOT-ES-20-015

Participating Organizations: (NIEHS)

Release Date: April 9, 2020

Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIDDK

NOT-DK-20-018

Participating Organizations: (NIDDK)

Release Date: April 9, 2020

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19)

NOT-DC-20-004

Participating Organizations: (NIDCD)

Release Date: April 9, 2020

NHLBI Announces Availability of Frequently Asked Questions (FAQs) for NOT-HL-20-757, Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)

NOT-HL-20-759

Participating Organizations: (NHLBI)

Release Date: April 8, 2020

Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)

NOT-AG-20-022

Participating Organizations: (NIA), (NIMH)

Release Date: April 2, 2020

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus

NOT-HG-20-030

Participating Organizations: (NHGRI)

Release Date: March 31, 2020

Notice of Special Interest: NIEHS Worker Training Program Coronavirus and Infectious Disease Response Training (Admin Supp Clinical Trial Not Allowed)

NOT-ES-20-014

Participating Organizations: (NIEHS)

Release Date: March 27, 2020

Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)

NOT-TR-20-012

Participating Organizations: (NCATS)

Release Date: March 27, 2020

Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome

NOT-AI-20-034

Participating Organizations: (NIAID)

Release Date: March 25, 2020

Notice of Early Expiration of “Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019

NOT-AI-20-040

Participating Organizations: (NIAID)

Release Date: March 25, 2020

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2

NOT-GM-20-025

Participating Organizations: (NIGMS)

Release Date: March 25, 2020

Notice of Special Interest (NOSI) Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need

NOT-TR-20-011

Participating Organizations: (NCATS)

Release Date: March 24, 2020

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus

NOT-DA-20-047

Participating Organizations: (NIDA)

Release Date: March 19, 2020

Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)

NOT-HL-20-757

Participating Organizations: (NHLBI)

Release Date: March 17, 2020

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV)

NOT-AI-20-030

Participating Organizations: (NIAID), (NIGMS)

Release Date: February 6, 2020

COSSA Resources for Researchers Related to COVID-19

https://www.cossa.org/resources/covid-19/
COSSA (Consortium of Social Science Associations) is compiling a list of resources for social scientists and stakeholders related to the COVID-19 pandemic. The list includes guidance from federal science agencies, collections of publicly available peer-reviewed research related to the crisis, resources from COSSA member associations, and more. There are a number of funding opportunities available for researchers related to COVID-19.

Department of Defense Opportunities

DOD Prototype Development to Combat COVID-19

The Medical Technology Enterprise Consortium (MTEC) is excited to post this pre-announcement for a potential Request for Project Proposals (RPP) focused on the development of prototypes aimed to combat the coronavirus (COVID-19). In light of the magnitude and potential threat that the coronavirus (COVID-19) poses to the military’s health and readiness, the government seeks to rapidly accelerate the inquiry, testing, and fielding of new 21st century capabilities, employing novel technologies and approaches to the detection of exposure, prevention, containment and treatment of COVID-19 and future emerging threats. MTEC believes that an emphasis will be placed on technologies that can be deployed as soon as possible but no later than 31 December 2020. In support of this, MTEC has identified the following potential areas of interest: Point-of-care diagnostic that provides rapid and accurate determination on exposure to COVID-19. Prophylactic(s)/Therapeutic(s) that can prevent and/or treat in a rapid manner (few hours to 2 days) potentially in a non-hospital environment. Repurposing FDA-approved drugs/biologics for prevention/treatment of COVID-19 or testing of drugs/biologics that have already demonstrated safety in humans for the prevention/treatment of COVID-19 are preferred.

Although there is no specific funding commitment by the U.S. Government at this time, MTEC believes that there may be tens of millions of dollars available for combating COVID-19 programs with a likelihood of follow-on funding. The upcoming RPP(s) will be posted to the MTEC website and a notice will be posted here to notify interested parties. Contingent upon approval from the Government, the upcoming RPP(s) is expected to be released within the next few weeks and will have an extremely short preparation period (approximately 14 days).

Application Deadline: TBA

Bill and Melinda Gates Foundation

Bill and Melinda Gates Foundation COVID-19 Therapeutics Accelerator Diagnostics

https://submit.gatesfoundation.org/prog/covid-19_therapeutics_accelerator_diagnostics_proposal_portal/

The Therapeutics Accelerator is committing funding to speed the response to the COVID-19 epidemic by playing a catalytic role in accelerating the evaluation of new and repurposed drugs and biologics to treat patients with COVID-19. The Therapeutics Accelerator is a collaborative effort committed to equitable access, including making products available and affordable in low-resource settings. Each proposal should be in line with the Therapeutics Accelerator’s guiding principles in order to qualify for review. We have highlighted the most relevant criteria here:

  • A focus on near-term impact
  • Global access through prompt launch, with a focus on vulnerable populations
  • Feasibility for use in low- and middle-income (LMIC) health systems
  • A willingness to share relevant data in near real-time

Bill and Melinda Gates Foundation COVID-19 Therapeutics Accelerator Preclinical Proposal

https://submit.gatesfoundation.org/prog/covid-19_therapeutics_accelerator_preclinical_proposal_portal/

The Therapeutics Accelerator is committing funding to speed the response to the COVID-19 epidemic by playing a catalytic role in accelerating the evaluation of new and repurposed drugs and biologics to treat patients with COVID-19. The Therapeutics Accelerator is a collaborative effort committed to equitable access, including making products available and affordable in low-resource settings. Each proposal should be in line with the Therapeutics Accelerator’s guiding principles in order to qualify for review. We have highlighted the most relevant criteria here:

  • A focus on near-term impact
  • Treatment of mild (outpatient) to moderate (early hospitalization) disease or pre-/post-exposure prophylaxis
  • Treatment modalities focused on small molecule drugs, monoclonal antibodies or other biologics
  • Global access through prompt launch, with a focus on vulnerable populations
  • Feasibility for use in low- and middle-income (LMIC) health systems
  • A willingness to share relevant data in near real-time

NSF Opportunities 

RAPID: Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19)

NSF encourages the research community to respond to this challenge through existing funding opportunities. In addition, they invite researchers to use the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency with regard to availability of or access to data, facilities or specialized equipment as well as quick-response research on natural or anthropogenic disasters and similar unanticipated events. Requests for RAPID proposals may be for up to $200,000 and up to one year in duration. Well-justified proposals that exceed these limits may be entertained. All questions should be directed either to a program officer managing an NSF program with which the research would be aligned or to this e-mail address.

Application Deadline: RAPIDs on rolling basis, others vary by directorate

Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19)

This Dear Colleague Letter (DCL) complements a separate National Science Foundation (NSF) DCL (NSF 20-052) that referred to the emergence of the coronavirus disease 2019 (COVID-19) and expressed NSF's interest in accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to better understand how to model and understand the spread of COVID-19; to inform and educate about the science of virus transmission and prevention; and to encourage the development of processes and actions to address this global challenge.

CDC Opportunities

https://www.cdc.gov/grants/public-health-emergencies/covid-19/index.html

CDC Crisis Response Mechanism for Funding State, Local, Territorial and Tribal (SLTT) Public Health Departments During a Public Health Response (TP-18-1802)

CDC has awarded nearly $730 million in funding under Components A and B of the cooperative agreement to the 65 eligible jurisdictions that are on the approved but unfunded (ABU) list for CDC-RFA-TP18-1802 to provide resources to prevent, prepare for, and respond to COVID-19. This funding is intended for state, local, territorial, and tribal health departments to carry out surveillance, epidemiology, laboratory capacity, infection control, mitigation, communications, and other preparedness and response activities.

Epidemiology and Laboratory Capacity for the Prevention and Control of Emerging Infectious Diseases (ELC) (CK19-1904 2019)

CDC 24/7 Response and Support for COVID-19 Activities

CDC has awarded nearly $730 million in funding under Components A and B of the cooperative agreement to the 65 eligible jurisdictions that are on the approved but unfunded (ABU) list for CDC-RFA-TP18-1802 to provide resources to prevent, prepare for, and respond to COVID-19. This funding is intended for state, local, territorial, and tribal health departments to carry out surveillance, epidemiology, laboratory capacity, infection control, mitigation, communications, and other preparedness and response activities.

PCORI Funding Opportunities

PCORI Funding Opportunity for COVID-19-Related Enhancements to Existing PCORI-Funded Research Projects

Deadline: applications currently accepted on a rolling basis

PCORI seeks investigator-initiated proposals to address the COVID-19 public health crisis through enhancements of currently funded PCORI research awards. Only PCORI-funded principal investigators with active research project funding contracts are eligible to submit a proposal in response to this announcement.

PCORI Funding Opportunity for COVID-19-Related Enhancements to Existing PCORI-Funded Engagement Awards

Deadline: applications currently accepted on a rolling basis

PCORI is currently seeking Project Lead-initiated proposals to address the COVID-19 public health crisis through enhancements to currently funded PCORI Engagement Awards. Only PCORI-funded project leads with active Engagement Award contracts are eligible to submit a proposal in response to this funding announcement.

InfoEd Global COVID-19/Coronavirus Resources for various funding Opportunities

https://www.infoedglobal.com/COVID19/COVID-19

InfoEd Global is proud to be able to share this library of COVID-19 funding opportunities and resources with our colleagues in the research realm and the broader community at large.

USDA Funding Opportunities

https://www.rd.usda.gov/sites/default/files/USDA_COVID-19_Fed_Rural_Resource_Guide.pdf

The COVID-19 Federal Rural Resource Guide is a helpful resource published by the U.S. Department of Agriculture unveiled by the USDA for rural communities looking for federal funding and partnership opportunities to help address COVID-19. This resource matrix organizes funding opportunities identified in the CARES Act and other federal resources that can help support rural America. Opportunities are categorized by customer and assistance type.

Research Forrest